Targanta Files for IPO

Targanta Therapeutics Inc., a Cambridge, Mass.-based developer of antibacterial agents, has filed for an $86.25 million IPO. It plans to trade on the Nasdaq under ticker symbol TARG, with Credit Suisse serving as lead underwriter. The company has raised $85 million in total VC funding since its 1997 inception, including a $70 million Series C round earlier this year. Shareholders include Brookside Capital Partners (15.2% pre-IPO position), InterMune Inc. (15.2%), Skyline Ventures (13.2%), VenGrowth (11.8%), OrbiMed Advisors (11.1%), T2C2 (7.3%), Canadian Medical Discoveries Fund (7.1%), Seaflower Ventures (7%) and Radius Ventures (6.1%). www.targanta.com